PGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Precigen Inc (PGEN) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown promising revenue growth and positive catalysts such as the FDA approval of PAPZIMEOS and optimistic Q1 revenue guidance, the stock's technical indicators, options sentiment, and financial performance suggest caution. The lack of strong proprietary trading signals and the bearish moving averages further support a 'hold' recommendation.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels, with a pre-market price of $3.82, which is below the pivot point of $3.565. This suggests limited upward momentum in the short term.
FDA approval of PAPZIMEOS, the first and only approved therapy for recurrent respiratory papillomatosis.
Strong Q1 2026 revenue guidance of over $18 million.
Positive analyst ratings with price target increases to $9 and $10, citing strong early commercial traction and broad market acceptance.
Hedge funds are aggressively selling, with an 801.59% increase in selling activity over the last quarter.
The company reported a significant net loss of $429.6 million in 2025, raising concerns about profitability.
Pre-market price decline of -1.80%, indicating weak short-term sentiment.
Precigen reported a 149% increase in full-year revenue for 2025, reaching $9.7 million, and a 288.40% YoY increase in Q4 revenue to $4.62 million. However, the company remains unprofitable, with a net loss of $23.5 million in Q4 2025 and a full-year net loss of $429.6 million. Gross margin improved significantly to 65.47%, but rising SG&A expenses continue to weigh on profitability.
Analysts are optimistic, with Citizens raising the price target to $9 and H.C. Wainwright raising it to $10. Both firms maintain positive ratings, citing strong early sales metrics for PAPZIMEOS and broad market acceptance. However, the stock's current price of $3.82 is significantly below these targets, suggesting potential upside but also reflecting market skepticism.
